JP2010515717A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515717A5
JP2010515717A5 JP2009545252A JP2009545252A JP2010515717A5 JP 2010515717 A5 JP2010515717 A5 JP 2010515717A5 JP 2009545252 A JP2009545252 A JP 2009545252A JP 2009545252 A JP2009545252 A JP 2009545252A JP 2010515717 A5 JP2010515717 A5 JP 2010515717A5
Authority
JP
Japan
Prior art keywords
beta
seq
antibody
cdr2
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009545252A
Other languages
English (en)
Other versions
JP2010515717A (ja
Filing date
Publication date
Priority claimed from EP07000507A external-priority patent/EP1944314A1/en
Priority claimed from EP07000521A external-priority patent/EP1944315A1/en
Application filed filed Critical
Priority claimed from PCT/IB2008/000456 external-priority patent/WO2008084402A2/en
Publication of JP2010515717A publication Critical patent/JP2010515717A/ja
Publication of JP2010515717A5 publication Critical patent/JP2010515717A5/ja
Pending legal-status Critical Current

Links

Description

【請求項６】
前記抗体は、特異的軽鎖ＣＤＲであるＣＤＲ１、ＣＤＲ２およびＣＤＲ３としてそれぞれ配列番号３３、配列番号４１；配列番号４５ならびに特異的重鎖ＣＤＲであるＣＤＲ１、ＣＤＲ２およびＣＤＲ３としてそれぞれ配列番号１５；配列番号２３および配列番号２９のアミノ酸配列を含んでなる、請求項１に記載の抗体。
【請求項１１】
前記抗体は、Ａβ（２１−３７）を含んでなるＡβポリペプチドに結合する場合、タンパク質分解消化からＡβ（２１−３７）の残基を遮蔽する、請求項１に記載の抗体。
【請求項１３】
前記抗体は、Ａβ（２１−３７）を含んでなるＡβポリペプチドに結合する場合、タンパク質分解消化からＡβ（２１−３７）の残基を遮蔽する、請求項１２に記載の抗体。

Claims (3)

  1. 前記抗体は、特異的軽鎖ＣＤＲであるＣＤＲ１、ＣＤＲ２およびＣＤＲ３としてそれぞれ配列番号３３、配列番号４１；配列番号４５ならびに特異的重鎖ＣＤＲであるＣＤＲ１、ＣＤＲ２およびＣＤＲ３としてそれぞれ配列番号１５；配列番号２３および配列番号２９のアミノ酸配列を含んでなる、請求項１に記載の抗体。
  2. 前記抗体は、Ａβ（２１−３７）を含んでなるＡβポリペプチドに結合する場合、タンパク質分解消化からＡβ（２１−３７）の残基を遮蔽する、請求項１に記載の抗体。
  3. 前記抗体は、Ａβ（２１−３７）を含んでなるＡβポリペプチドに結合する場合、タンパク質分解消化からＡβ（２１−３７）の残基を遮蔽する、請求項１２に記載の抗体。
JP2009545252A 2007-01-11 2008-01-11 アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置 Pending JP2010515717A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US88452607P 2007-01-11 2007-01-11
US88451307P 2007-01-11 2007-01-11
EP07000507A EP1944314A1 (en) 2007-01-11 2007-01-11 Diagnosis of Alzheimer's disease and other neurodementing disorders
EP07000521A EP1944315A1 (en) 2007-01-11 2007-01-11 Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases
US98166707P 2007-10-22 2007-10-22
US98167507P 2007-10-22 2007-10-22
EP07119026 2007-10-22
EP07119002 2007-10-22
PCT/IB2008/000456 WO2008084402A2 (en) 2007-01-11 2008-01-11 Diagnosis and treatment of alzheimer's and other neurodementing diseases

Publications (2)

Publication Number Publication Date
JP2010515717A JP2010515717A (ja) 2010-05-13
JP2010515717A5 true JP2010515717A5 (ja) 2011-03-31

Family

ID=39609117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545252A Pending JP2010515717A (ja) 2007-01-11 2008-01-11 アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置

Country Status (11)

Country Link
US (3) US7939075B2 (ja)
EP (1) EP2104682B1 (ja)
JP (1) JP2010515717A (ja)
AU (1) AU2008204335B2 (ja)
CA (1) CA2675340C (ja)
DK (1) DK2104682T3 (ja)
ES (1) ES2610474T3 (ja)
PL (1) PL2104682T3 (ja)
SI (1) SI2104682T1 (ja)
TW (1) TW200844110A (ja)
WO (1) WO2008084402A2 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2143447A1 (en) * 2008-07-11 2010-01-13 Universität Konstanz Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease
WO2010095940A2 (en) * 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제
DE102009034119A1 (de) * 2009-07-20 2011-01-27 Philipps-Universität Marburg Verfahren, insbesondere Enzyme-linked Immunosorbent Assay (ELISA), zum in vitro Nachweis von Amyloid beta Autoantikörpern, Mikrotiterplatte und Testkit
DK2921486T3 (da) 2009-08-07 2017-11-13 American Life Science Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af beta-amyloid-relaterede sygdomme
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2496341T3 (es) * 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
KR101190573B1 (ko) * 2011-10-07 2012-10-18 대한민국 혈액 내 아밀로이드-베타 항체에 특이적으로 결합하는 신규 Ａβ２２（ｐＥ）－４２ 펩티드를 유효성분으로 포함하는 치매 진단용 키트
US20130273574A1 (en) * 2012-03-13 2013-10-17 Janssen Alzheimer Immunotherapy Oligomeric a-beta in the diagnosis, prognosis, and monitoring of alzheimer's disease
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP6582995B2 (ja) * 2014-01-21 2019-10-02 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
ES2663623T3 (es) * 2015-01-12 2018-04-16 Heraeus Deutschland GmbH & Co. KG Uso de una composición eléctricamente conductora como adhesivo eléctricamente conductor para conectar mecánica y eléctricamente conductores eléctricos con los contactos eléctricos de células solares
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
EP3728323A4 (en) * 2017-12-19 2022-01-26 Surrozen Operating, Inc. ANTI-FZD ANTIBODIES AND METHODS OF USE
EP3732201A4 (en) * 2017-12-19 2022-04-20 Surrozen Operating, Inc. WNT SUBSTITUTION MOLECULES AND THEIR USES
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DE69432629T3 (de) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP2305709A1 (en) 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2001042306A2 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
US20030083277A1 (en) 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
CN101670105B (zh) 2000-02-24 2014-08-06 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
NZ522700A (en) * 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20050208050A1 (en) 2001-11-09 2005-09-22 Gerd Multhaup Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2003051374A2 (en) 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
US8871447B2 (en) 2002-09-12 2014-10-28 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
WO2004031400A2 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20050106626A1 (en) 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
MXPA05005160A (es) * 2002-11-15 2005-07-22 Genmab As Anticuerpos monoclonales humanos contra la cd25.
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
RU2006122946A (ru) * 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
PL1720909T3 (pl) 2004-02-23 2012-04-30 Lilly Co Eli Przeciwciało anty-abeta
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
CA2584859C (en) 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
EP2284194A1 (en) * 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
AR052469A1 (es) 2005-01-28 2007-03-21 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2007062088A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
RU2015111675A (ru) 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
KR101413615B1 (ko) 2006-03-23 2014-07-18 바이오악틱 뉴로사이언스 에이비 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
EP2114984A2 (en) * 2007-01-17 2009-11-11 Merck Serono S.A. Process for the purification of fc-containing proteins
CA2714413C (en) * 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof

Similar Documents

Publication Publication Date Title
JP2010515717A5 (ja)
NZ605980A (en) Anti-fap antibodies and methods of use
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
JP2009225799A5 (ja)
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
JP2012507294A5 (ja)
JP2017176174A5 (ja)
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
HRP20190643T1 (hr) Protutijela protiv dkk-1
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
NZ592151A (en) Anti-igf antibodies
JP2014526898A5 (ja)
JP2011173884A5 (ja)
JP2018033454A5 (ja)
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ712667A (en) Rsv-specific binding molecules and means for producing them
JP2010502207A5 (ja)
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
JP2012502649A5 (ja)
JP2014509837A5 (ja)
NZ712765A (en) Antibodies that bind csf1r